DIRS.INFO The most relevant business & tech news

☆ Cigna, Humana shares fall after report health-care giants are in talks to merge
▼ + stars: | 2023-11-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Shares of Cigna and Humana slid Wednesday after a report that the two health-care giants are in talks to merge. A Cigna spokesperson did not immediately respond to CNBC's request for comment on the report from The Wall Street Journal, which cited people familiar with the matter. A Humana spokesperson declined to comment. A Cigna spokesperson at the time said the company does not comment on "rumors or speculation." Some analysts have suggested that a potential combination with Humana could be a reason for Cigna to offload its Medicare Advantage business.

Persons: Humana's, Cigna, Scott Fidel, Stephens, Fidel Organizations: Humana, Wall Street, STAT, CNBC PRO

☆ Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says
▼ + stars: | 2023-11-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or obese adults, according to a large analysis of real-world data published Monday. The results come as both drugs and similar treatments approved for weight loss soar in demand in the U.S. for their ability to help patients shed unwanted pounds over time. Previous head-to-head studies have similarly suggested that Mounjaro is more effective than Ozempic for weight loss and controlling blood sugar in adults with Type 2 diabetes. But Monday's study confirms Mounjaro's edge over Ozempic in a real-world setting, specifically among adults who are overweight or obese. Eli Lilly is pitting Mounjaro against Wegovy, a higher-dose version of Ozempic approved for weight loss, in an ongoing clinical trial in obese or overweight patients.

Persons: Eli Lilly, Mounjaro, We've, Nick Stucky Organizations: Novo Nordisk, Truveta Research, Research, Wegovy Locations: U.S

☆ U.S. to offer another round of free at-home Covid tests starting Monday
▼ + stars: | 2023-11-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

COVID-19 home test kits are pictured in a store window during the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., January 19, 2022. The Biden administration on Monday said it is offering another round of free at-home Covid tests to U.S. households ahead of the holiday season, when more people gather indoors and the virus typically spreads at higher levels. Starting Monday, Americans can use COVIDtests.gov to request four free tests per household. Those who have not ordered any tests this fall can now place two orders for a total of eight tests, according to the website. The administration in September allowed people to request an initial round of four free tests through the site, resuming a federal program that temporarily shut down during a political fight over Covid funding.

Persons: Biden Locations: Manhattan, New York City , New York, U.S

☆ Tips for achieving work-life balance
▼ + stars: | 2023-11-18 | by ( Diamond Naga Siu | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at how the pandemic has twisted our perceptions of work-life balance — in good and bad ways. And that's impacted how people see and achieve work-life balance. AdvertisementMore than 60% of employees consider work-life balance a top priority in their next job, according to a 2022 Gallup study. She highlighted how people aren't just aspiring for work-life balance — they've come to expect it. Experts shared tips on small ways to improve your work-life balance.

Persons: —, hangouts, Julie Tran, Gen Zers, Kristen Lipton, Ryan Anderson, Anderson, Lipton, that's, Fernando Constantino Martínez Belmar, Xi, It's, Royce, That's, Zers, Tom Farley, Stella Kalinina, Drake, it's, you've, Naga Siu, Dan DeFrancesco, Hallam Bullock, Lisa Ryan Organizations: Service, Gallup, Future, Drayson Locations: Hochatown , Oklahoma, Loma Linda , California, San Diego, New York City, London

☆ CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
▼ + stars: | 2023-11-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The shortage – and other issues related to insurance coverage – threatens to prevent infants from receiving critical protection against RSV. Each year, the virus kills a few hundred children younger than 5, and 6,000 to 10,000 seniors, according to the CDC. RSV also causes around 58,000 to 80,000 hospitalizations among children younger than 5 years old each year, the CDC said. The U.S. started to see a sharp uptick in RSV cases in the middle of October. The U.S. suffered an unusually severe RSV season last year.

Persons: Sanofi, Nirav Shah Organizations: Disease Control, U.S, Sanofi, AstraZeneca, CDC, Vaccines, Children Program, Food and Drug Administration, FDA Locations: U.S

☆ Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
▼ + stars: | 2023-11-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Those companies helped spark the weight loss drug industry gold rush over the last year with their weekly obesity and diabetes injections, such as Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro. They want to see the drug cause a similar level of weight loss as a once-daily pill from Eli Lilly. "If Pfizer's data is positive, then I think people might be able to look beyond all this Covid overhang," Cantor Fitzgerald analyst Louise Chen told CNBC. A weight loss pill could be a boon for all three companies.

Persons: Eli Lilly, Eli Lilly's Mounjaro, Albert Bourla, –, Cantor Fitzgerald, Louise Chen Organizations: Pfizer, Novo Nordisk, Nordisk's Wegovy, CNBC

☆ Eli Lilly and more: Strategist names 5 stocks set for 'significant' earnings growth
▼ + stars: | 2023-11-10 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

Rising rates and the possibility of a recession on the horizon have created a "mixed picture" for equity markets, according to one strategist — but several companies can look forward to markedly stronger earnings growth in the next year. "But, if you're looking for significant earnings expansion, I suspect, at a market level, that's probably less likely. The earnings growth rate for the S & P 500 was 3.7% year-on-year – the first quarter with year-on-year growth since the third quarter of 2022, the data showed. "What Eli Lilly is going to do with their weight loss drug is not dependent on whether the rates are 5.2% or 4.8%. "People didn't really talk about [Adobe] — everyone assumed that they were going to be a loser from AI," he said.

Persons: —, they're, Rahul Ghosh, Rowe Price, Ghosh, Eli Lilly, Powell, Software Ghosh, — CNBC's Annika Kim Constantino Organizations: Healthcare Healthcare, UnitedHealth Group, Fellow, Food and Drug Administration, Software, Adobe Creative, Adobe Express

☆ Pharmacy walkout organizers help launch national push to unionize pharmacists, technicians
▼ + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The organizers of a recent retail pharmacy staff walkout are helping to launch a national push to organize those employees on Wednesday, a potential step to wide-scale unionization of thousands of pharmacists and technicians across the U.S. for the first time. Both Walgreens and CVS also said last week that the walkout of their pharmacy staff last week had a minimal impact on their pharmacy operations. IAM Healthcare and the walkout organizers will then launch unionization campaigns in certain districts or areas with high support for organizing. The Pharmacy Guild hopes to get 100,000 pharmacists and technicians to fill out the form, Jerominski said. He also predicted that 90% of pharmacists working for Walgreens and CVS will be unionized in five years.

Persons: unionize, Shane Jerominski, aren't, Jerominski Organizations: Walgreens, IAM Healthcare, CVS, Kroger, CNBC Locations: Deerfield , Illinois

☆ FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
▼ + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

George Frey | ReutersThe Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The FDA said the approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average. The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Preliminary data is already available: A recent late-stage trial found that Novo Nordisk's weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%.

Persons: George Frey, Eli Lilly, John Sharretts, Eli Lilly's, Wegovy, Lilly, Mike Mason, Eli Lilly Diabetes Organizations: Novo Nordisk, Pharmacy, Reuters, Food, Drug Administration, U.S, FDA's Center, Drug, FDA, Obesity Locations: Provo , Utah, U.S, United States

☆ Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk on Thursday said 80% of U.S. patients with insurance coverage who take its highly popular weight loss treatment Wegovy are paying less than $25 a month for the drug. He estimated that about 50 million Americans with obesity could be eligible for Wegovy coverage under their health plans. Most patients have to take Wegovy for several months to see — and sustain — significant weight loss. Wegovy, for example, leads to 15% weight loss after 68 weeks, according to clinical trials on the drug. But Novo Nordisk is hoping that new data demonstrating the heart health benefits of Wegovy will put more pressure on insurers to cover the medication and similar weight loss treatments.

Persons: Doug Langa, Langa, Eli Lilly, Karsten Munk Knudsen, Wegovy Organizations: Novo Nordisk, balk, Novo Nordisk's, North, Nordisk, CNBC, U.S . Food, Drug Administration, National Institutes of Health Locations: U.S, Novo, North America

☆ Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread shortages. During an earnings call Thursday, Eli Lilly executives said the company experienced tight supply for Mounjaro throughout most of the third quarter. But U.S. product shipments of Mounjaro have recently increased, and inventory levels at U.S. drug wholesalers have improved, according to Eli Lilly CFO Anat Ashkenazi. Eli Lilly has also invested more than $3 billion to build two new manufacturing sites in its home state of Indiana. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , is still navigating its own supply constraints of diabetes drug Ozempic and obesity treatment Wegovy.

Persons: Eli Lilly, Mounjaro, Eli Lilly's, Anat Ashkenazi, Ashkenazi, David Ricks, Ricks, we're, Wegovy, Eli Lilly's Mounjaro Organizations: Novo Nordisk, Pharmacy, Food, Pfizer Locations: Provo , Utah, U.S, North Carolina, Indiana, Novo

☆ Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions. Eli Lilly recorded pre-tax "in-process research and development" charges of $2.98 billion, which are primarily related to a slew of recent buyouts, including DICE Therapeutics, Versanis Bio and Emergence Therapeutics AG. "This is essentially the future value of business development deals we have done," Eli Lilly CEO David Ricks said on CNBC's "Squawk Box" on Thursday. But Eli Lilly reiterated its full-year revenue forecast of between $33.4 billion and $33.9 billion. With a market cap of roughly $526 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, Jardiance, David Ricks Organizations: LSEG, Therapeutics, U.S Locations: Mounjaro, Wednesday's

☆ Moderna stock falls 10% as hefty Covid vaccine write-downs drive big loss
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Thursday posted a steep loss for the third quarter as the drugmaker recorded a large write-down due to unused doses of its Covid vaccine, its only marketable product. Revenue: $1.83 billion vs. $1.40 billion expectedShares of Moderna fell more than 10% in premarket trading Thursday. Moderna posted a net loss of $3.63 billion, or $9.53 per share, for the quarter. The biotech company generated third-quarter sales of $1.83 billion, with sales of its Covid shot dropping 44% from the same period a year ago. In August, Moderna said it expected its shot to rake in $6 billion to $8 billion in revenue in 2023.

Persons: Stéphane Bancel, Bancel, Moderna Organizations: Moderna, LSEG, Revenue Locations: U.S

☆ CVS results top expectations, lifted by strong health services revenue
▼ + stars: | 2023-11-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

CVS on Wednesday reported third-quarter adjusted earnings and revenue that topped Wall Street's expectations, lifted in part by strong revenue from the company's health services business. CVS booked sales of $89.76 billion for the quarter, up nearly 11% from the same period a year ago. The company reported net income of $2.27 billion, or $1.75 per share, for the third quarter. Excluding certain items, such as amortization of intangible assets and capital losses, adjusted earnings per share were $2.21 for the quarter. However, it maintained its forecast on an adjusted basis, guiding to full-year adjusted earnings of $8.50 to $8.70 per share.

Organizations: CVS, LSEG, Walgreens, Aid, CNBC, Oak Street Health Locations: Monday's

☆ Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
▼ + stars: | 2023-10-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Tuesday reported a narrower-than-expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and the Covid vaccine. Pfizer said it recorded a $5.6 billion charge for inventory write-offs in the third quarter due to lower-than-expected use of Covid products. Of these write-offs, $4.7 billion is chalked up to Paxlovid and $900 million is attributed to the company's vaccine. For the third quarter, Pfizer booked a net loss of $2.38 billion, or 42 cents per share. Meanwhile, the pharmaceutical giant expects its Covid antiviral treatment Paxlovid to bring in $1 billion in revenue.

Persons: Paxlovid Organizations: Pfizer, LSEG, U.S . Locations: U.S, Monday's

☆ Here's how to take .5 selfies — the super wide-angle shots that Gen Z loves
▼ + stars: | 2023-10-29 | by ( Ashley Capoot | ) www.cnbc.com time to read: +7 min

Members of Gen Z take .5 selfies. On platforms like Instagram , for instance, Gen Z users don't favor a perfectly curated feed full of posed and filtered photos. Members of Gen Z take .5 selfies. "I think that's why Gen Z goes insane over the Tube Girl." How to take a .5 selfieA member of Gen Z takes a .5 selfie.

Persons: Gen, Duncan Grant, Rebecca Smith, Rachel Aquino, Gabriel Lesser, Riley Galfi, Galfi, Aidan Bissett, Gen Z, Aquino, it's, I'm, Lesser, Emma Kelly, Annika Kim Constantino, Alix Earle, Emma Chamberlain, Louis Vuitton, Sabrina Bahsoon, Bahsoon Organizations: CNBC, Apple, Pew Research Center, Spotify Locations: New York, London

☆ Some pharmacy staff from Walgreens, other chains are walking out again — here's what you need to know
▼ + stars: | 2023-10-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +11 min

The company's ongoing efforts are focused on how it can recruit, retain and reward pharmacy staff, the spokesperson said. CVS pharmacists make $61.44 an hour on average, while Walgreens pharmacists make $53.85 per hour on average, according to employment website Indeed. However, some Walgreens pharmacy staff told CNBC that the company continues to push their stores to hit performance goals for tasks like verifying prescriptions. IAM Healthcare did not immediately respond to a request for comment, while UFCW has expressed its support for the recent walkouts staged by Walgreens and CVS pharmacy staff. People make their way near a Walgreens pharmacy in New York City, March 9, 2023.

Persons: Brian Snyder, Shane Jerominski, walkouts, Stephanie Keith, I've, Irfan Khan, aren't, Jerominski, UFCW, Leonardo Munoz Organizations: Walgreens, Reuters, CNBC, CVS, Rite Aid, Kansas City, Bloomberg, Getty, Food and Drug Administration, Pfizer, CVS Pharmacy, Los Angeles Times, Kroger, IAM Healthcare, United Food, Commercial Workers International Union, Corbis Locations: Somerville , Massachusetts, Kansas City, Kansas, U.S, Massachusetts , Pennsylvania, California , Texas , Michigan , Missouri, Indiana, New York, Eagle Rock , CA, Canada, New York City

☆ Pharmacy staff from Walgreens, CVS say they’re at a breaking point — here’s what their days look like
▼ + stars: | 2023-10-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +7 min

Those investments include enabling teams to schedule additional support as needed, enhancing pharmacist and technician recruitment and hiring and strengthening pharmacy technician training, according to the spokesperson. The pharmacist typically begins the shift by completing several paperwork tasks, which take about five to 10 minutes. The pharmacist and a pharmacy technician then juggle administering shots with several other tasks. The technician typically handles the first part of that task, which involves processing new prescription orders from doctors. One CVS pharmacy technician said they typically come to their store location at 7:50 a.m., 10 minutes before their eight-hour shift starts.

Persons: Mandel Ngan, weren't, Brian Snyder, —, Spencer Platt Organizations: AFP, Getty, Walgreens, CVS, CNBC, Reuters Locations: Washington ,, Somerville , Massachusetts, Brooklyn, New York City

☆ Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth
▼ + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. Merck lowered its adjusted profit guidance to $1.33 to $1.38 per share, from a previous forecast of $2.95 to $3.05 a share. But that updated outlook reflects an upfront charge of $5.5 billion, or $1.70 per share, related to the company's recent drug collaboration agreement with Daiichi Sankyo. Excluding Lagevrio, pharmaceutical sales grew 9%. The Covid antiviral treatment brought in $640 million in sales for the quarter, up 47% from the third quarter of 2022.

Persons: Merck Organizations: Merck, Prometheus Biosciences, Imago BioSciences, Kelun, Biotech, LSEG, U.S Locations: Japan, Australia

☆ Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
▼ + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company's popular blood cancer drug Revlimid plummeted due to generic competition. Bristol Myers also reiterated its full-year revenue guidance of a low single-digit percentage decline. Bristol Myers said both older and new drug products helped offset the lower sales of Revlimid for the third quarter. Eliquis, which Bristol Myers shares with Pfizer , is among the first ten drugs selected to face price negotiations with the federal Medicare program. Bristol Myers will hold an earnings call with investors at 8 a.m. E.T.

Persons: Revlimid, Bristol Myers, –, Eliquis, FactSet, Opdualag Organizations: Bristol Myers Squibb, Bristol, LSEG, Pfizer, FactSet, Therapeutics Locations: Wednesday's

☆ Pfizer's combination Covid, flu vaccine will move to final-stage trial after positive data
▼ + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. Covid vaccine rates in the U.S. were bleak last year, and could look the same this year. The trial measured the safety, tolerability and efficacy of Pfizer's combination vaccine candidates among adults ages 18 to 64. The results showed that "lead" formulations of Pfizer's combination vaccine demonstrated robust immune responses to influenza A, influenza B and Covid strains, according to Pfizer. The safety profiles of the combination vaccine candidates were also consistent with the company's Covid vaccine.

Persons: BioNTech, Annaliesa Anderson, Pfizer's, Albert Bourla Organizations: Pfizer, BioNTech, Moderna Locations: U.S

☆ RSV vaccine from GSK shows potential to protect adults 50 to 59
▼ + stars: | 2023-10-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. Currently, Arexvy is approved in the U.S., Europe, Japan and other countries for adults ages 60 and older. A single dose of the British drugmaker's shot elicited an immune response in adults ages 50 to 59 who are at an increased risk of catching RSV due to certain underlying medical conditions. The immune response wasn't worse than that observed in adults 60 and above, GSK said in a release. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK.

Persons: Tony Wood Organizations: GlaxoSmithKline, Arexvy, GSK, Food and Drug Administration Locations: U.S, Europe, Japan, British

☆ More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
▼ + stars: | 2023-10-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eisai on Wednesday said an injectable version of the Alzheimer's drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment. Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March. Eisai presented the preliminary results, from an extension to a late-stage trial that supported the approval of intravenous Leqembi, at the Clinical Trials on Alzheimer's Disease conference in Boston. The study specifically showed that the injectable form of Leqembi removed 14% more plaque than the approved intravenous formulation. Blood concentration levels of the drug were 11% higher with subcutaneous Leqembi than the other version.

Persons: Eisai, Leqembi, Biogen, – Organizations: Eisai, ARIA, Alzheimer's Association Locations: U.S, Boston

☆ Sanofi to offer insulin product for $35 to all Americans through GoodRx
▼ + stars: | 2023-10-19 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Sanofi Lantus brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Americans, regardless of their insurance status, can now access Sanofi 's most widely prescribed insulin for $35 through the prescription drug savings company GoodRx , the companies announced Thursday. But some patients have struggled to access the $35 price point, even with that program in place. President Joe Biden's Inflation Reduction Act also capped monthly insulin costs for Medicare beneficiaries at $35, but it did not provide protection to diabetes patients who have private insurance. Approximately 8.4 million diabetes patients rely on insulin, the American Diabetes Association said.

Persons: Sanofi, Eli Lilly, Joe Biden's Organizations: Sanofi, CVS, Walgreens, Walmart, Sanofi –, Novo Nordisk –, U.S, Pharma, Life Sciences, Centers for Disease Control, American Diabetes Association Locations: Brooklyn, New York, U.S

☆ CVS to pull certain cold medicines containing decongestant phenylephrine from store shelves
▼ + stars: | 2023-10-19 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

CVS is removing some of the most common cough and cold medicines from its store shelves and will no longer sell them, a company spokesperson told CNBC on Thursday. However, CVS is voluntarily removing certain cough and cold medicines that contain phenylephrine as the only active ingredient from stores. They added that CVS stores will continue to offer other oral cough and cold products to meet patient needs. Oral products that list phenylephrine as its only active ingredient include Sudafed PE, which is marketed by Johnson & Johnson's consumer health spinoff Kenvue . Pulling oral phenylephrine from the market entirely could affect CVS and other retail pharmacy chains, which rake in revenue from selling over-the-counter cold and allergy pills.

Persons: Johnson, Kenvue Organizations: CNBC, Food and Drug Administration, FDA, CVS, Street Journal Locations: U.S

Search resuls for: "Constantino"

25 mentions found